Basel, Switzerland / Leiden, The Netherlands (September 25, 2008) - Lonza (Swiss Exchange: LONN) and Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) entered into a co-exclusive manufacturing, sales and distribution agreement related to the PERMEXCIS™ cell culture medium developed by Crucell for PER.C6® cells. Under this agreement, Lonza will manufacture the medium, and in addition will market and sell it on a global basis. Financial details of the agreement were not disclosed.
